We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagUS

18889881171

MSFT 417.6 -0.3674% AAPL 233.8413 1.0987% NVDA 131.796 -4.5441% GOOGL 165.105 0.0879% GOOG 166.53 0.1082% AMZN 186.945 -0.3173% META 585.25 -0.8756% AVGO 176.46 -3.2088% TSLA 220.1722 0.4619% TSM 187.28 -2.5649% LLY 912.1201 -1.8709% V 279.38 -0.4632% JPM 223.51 0.9166% UNH 558.27 -7.7849% NVO 117.56 -1.8534% WMT 81.405 1.3887% LVMUY 129.75 -6.7888% XOM 120.9 -2.5629% LVMHF 649.99 -6.7827% MA 507.335 0.1332%

Pharma Mar SAU

Healthcare US PHMMF

71.2USD
18.66(35.52%)

Last update at 2024-10-15T15:04:00Z

Day Range

69.8071.20
LowHigh

52 Week Range

32.0968.18
LowHigh

Fundamentals

  • Previous Close 52.54
  • Market Cap832.70M
  • Volume200
  • P/E Ratio53.79
  • Dividend Yield1.52%
  • EBITDA11.06M
  • Revenue TTM168.46M
  • Revenue Per Share TTM9.37
  • Gross Profit TTM 182.70M
  • Diluted EPS TTM0.86

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 43.79M 95.13M 145.61M -21.65400M -18.70400M
Minority interest - - 0.00000M -3.91800M -3.90000M
Net income 49.36M 92.86M 137.26M -11.37900M -5.53500M
Selling general administrative 19.02M 17.37M 13.52M 13.88M 17.43M
Selling and marketing expenses 24.22M 22.37M 22.26M 23.94M 41.82M
Gross profit 182.70M 213.39M 256.24M 80.59M 126.30M
Reconciled depreciation 5.90M 5.58M 7.21M 6.05M 6.86M
Ebit 48.42M 98.39M 149.00M -17.49700M -14.07300M
Ebitda 54.32M 103.98M 156.21M -11.44200M -7.21100M
Depreciation and amortization 5.90M 5.58M 7.21M 6.05M 6.86M
Non operating income net other - - - - 0.00000M
Operating income 44.07M 92.45M 155.94M -17.48600M -14.07200M
Other operating expenses 151.91M 137.48M 113.75M 103.29M 176.31M
Interest expense 2.38M 3.37M 3.12M 3.89M 4.71M
Tax provision -5.56600M 2.27M 8.34M -12.47400M -2.49900M
Interest income 0.88M 0.37M 0.34M 0.04M 0.07M
Net interest income -1.50100M -3.00300M -2.78800M -3.85300M -4.63900M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -5.56600M 2.27M 8.34M -12.47400M -2.49900M
Total revenue 196.34M 229.83M 269.96M 85.82M 162.16M
Total operating expenses 138.27M 121.04M 100.03M 98.07M 140.45M
Cost of revenue 13.64M 16.44M 13.72M 5.23M 35.87M
Total other income expense net -0.28100M 2.68M -10.33800M -4.16800M -4.63200M
Discontinued operations - - - -2.21700M 11.55M
Net income from continuing ops 49.36M 92.86M 137.26M -9.18000M -16.20500M
Net income applicable to common shares 49.36M 92.86M 137.26M -11.37900M -5.53500M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 393.26M 368.39M 330.26M 124.70M 157.68M
Intangible assets 2.59M 3.23M 3.86M 6.07M 16.66M
Earning assets - - - - -
Other current assets 23.11M 22.56M 10.49M 5.60M 3.15M
Total liab 170.30M 190.47M 227.54M 117.25M 140.20M
Total stockholder equity 222.96M 177.92M 102.72M 11.37M 21.37M
Deferred long term liab 1.40M 2.10M 2.81M 5.15M 5.48M
Other current liab 19.36M 5.83M 4.90M 2.58M 2.95M
Common stock 11.01M 11.01M 11.01M 11.13M 11.13M
Capital stock 11.01M 11.01M 11.01M 11.13M 11.13M
Retained earnings 156.51M 121.29M 41.87M -69.55200M -58.80600M
Other liab 45.09M 68.82M 92.74M 2.03M 2.90M
Good will - - - 0.00000M 2.55M
Other assets 30.56M 34.41M 37.89M 47.24M 42.55M
Cash 149.81M 113.35M 96.21M 17.64M 22.75M
Cash and equivalents - - - - -
Total current liabilities 97.32M 86.35M 94.92M 60.44M 72.38M
Current deferred revenue 35.74M 39.55M 52.20M 10.06M 9.71M
Net debt -107.18300M -64.01500M -39.54500M 68.48M 70.66M
Short term debt 14.73M 14.03M 16.78M 31.33M 28.48M
Short long term debt 13.12M 12.21M 15.31M 29.66M 28.48M
Short long term debt total 42.63M 49.33M 56.66M 86.11M 93.41M
Other stockholder equity 55.43M 45.62M 49.84M 69.79M 69.05M
Property plant equipment 36.94M 26.90M 24.75M 25.60M 25.47M
Total current assets 275.18M 295.23M 245.65M 49.98M 75.11M
Long term investments - - - 1.03M 0.88M
Net tangible assets 221.77M 176.79M 101.74M 10.52M 7.72M
Short term investments 32.61M 88.53M 99.31M 3.26M 4.13M
Net receivables 41.91M 60.26M 27.71M 14.58M 23.55M
Long term debt 25.88M 33.39M 37.73M 53.06M 64.92M
Inventory 27.75M 10.54M 11.93M 8.90M 20.62M
Accounts payable 27.49M 26.93M 21.04M 16.47M 31.23M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - - 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 33.45M 89.38M 100.15M 4.80M 10.20M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 118.08M 73.16M 84.61M 74.73M 82.57M
Capital lease obligations 3.62M 3.73M 3.62M 3.40M 0.00000M
Long term debt total - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 10.88M 26.27M -116.00700M -0.01900M -0.00400M
Change to liabilities 1.79M 7.18M 4.65M 5.50M 0.55M
Total cashflows from investing activities 10.88M 18.47M -119.00900M 32.07M 22.74M
Net borrowings -8.65800M -9.43800M -31.53900M -14.04900M -6.59700M
Total cash from financing activities -13.37000M -27.41500M -73.82000M -11.03800M -7.25700M
Change to operating activities -34.40800M -43.23000M 138.95M -0.14200M -15.19500M
Net income 43.79M 95.13M 145.61M -23.32200M -7.68900M
Change in cash 36.47M 17.14M 78.57M -5.10700M -1.34400M
Begin period cash flow 113.35M 96.21M 17.64M 22.75M 24.09M
End period cash flow 149.81M 113.35M 96.21M 17.64M 22.75M
Total cash from operating activities 38.32M 25.68M 278.94M -26.13700M -16.34000M
Issuance of capital stock 57.23M 33.55M 30.37M 8.56M 2.79M
Depreciation 5.90M 5.58M 7.21M 6.05M 6.86M
Other cashflows from investing activities - - - 2.64M 3.33M
Dividends paid -11.76100M -10.87200M -8.81900M 8.82M 6.92M
Change to inventory -17.21000M 1.40M -3.03100M -2.41800M -2.02900M
Change to account receivables 21.61M -26.76100M -12.63000M -16.52100M 3.30M
Sale purchase of stock -50.17800M -40.65900M -63.70800M -7.48100M -3.44600M
Other cashflows from financing activities 1.54M 5.83M 0.71M 4.79M 17.15M
Change to netincome 11.29M -11.35700M 6.53M -7.28200M -4.29300M
Capital expenditures 8.85M 7.80M 3.00M 3.91M 2.38M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -28.22000M -61.40800M 127.94M -13.58200M -13.29600M
Stock based compensation 0.39M 0.34M 0.27M 0.27M 0.80M
Other non cash items 1.79M 2.82M 2.38M 3.65M -5.69600M
Free cash flow 29.47M 17.87M 275.94M -30.04800M -18.71500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PHMMF
Pharma Mar SAU		 18.66 35.52% 71.20 53.79 - 4.94 3.60 4.09 39.64
NVO
Novo Nordisk A/S		 -2.22 1.85% 117.56 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.45 0.38% 119.55 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.745 0.36% 483.07 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.10 0.0099% 1014.35 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Pharma Mar SAU

Avenida de los Reyes, 1, Madrid, Spain, 28770

Key Executives

Name Title Year Born
Mr. Jose Maria Fernandez Sousa-Faro Founder, Exec. Chairman, CEO & Pres NA
Mr. Pedro Francisco Fernandez Puentes Exec. Vice-Chairman NA
Mr. Juan Carlos-Torres Carretero Founder 1949
Ms. María Luisa de Francia Caballero Chief Financial Officer NA
Ms. Elena Calleja Crespo Director of Fin. & Admin. NA
Mr. José Luis Moreno Martinez-Losa Director of Capital Markets & Investor Relations NA
Mr. Juan Gomez Pulido Gen. Counsel & Sec. of the Board of Directors NA
Ms. Sandra Llamera Sanchez Global Compliance Head NA
Ms. Lara Vadillo Communication Director NA
Mr. Juan Nogues Director of International Marketing & Sales NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.